RxDoctor Payments Data

Vernon Valentino, MD

Cardiovascular Disease · Lafayette, LANPI 1891787784

Payments from drug & device makers

$4,597in general payments, 2019–2025

Across 271 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$551
  • Merck$404
  • E.r. Squibb & Sons, L.L.C.$382
  • Novartis$374
  • Johnson & Johnson$370
  • AstraZeneca$354
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,588100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,597 in reported general payments places this provider in the 55th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$489,480
Medicare patients
1,139
Services billed
6,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban563$496,305
EntrestoSacubitril/Valsartan223$206,867
XareltoRivaroxaban143$140,049
Repatha SureclickEvolocumab91$69,522
FarxigaDapagliflozin Propanediol66$48,781
MultaqDronedarone Hcl18$20,613
VascepaIcosapent Ethyl22$13,494
Bisoprolol Fumarate405$9,910
Rosuvastatin Calcium645$9,846
EdarbiAzilsartan Medoxomil29$8,862
Metoprolol Succinate519$6,275
Ezetimibe250$6,193
Potassium Chloride220$5,183
Ranolazine ErRanolazine75$5,162
Atorvastatin Calcium403$4,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$219$496,305563 claims
NovartisEntresto$374$206,867223 claims
Johnson & JohnsonXarelto$370$140,049143 claims
AstraZenecaFarxiga$354$48,78166 claims
Sanofi-aventis U.S. LLCMultaq$244$20,61318 claims
Arbor Pharmaceuticals, Inc.Edarbi$110$8,86229 claims
Kowa Pharmaceuticals America, Inc.Livalo$128$3,32512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →